Shopping Cart
- Remove All
Your shopping cart is currently empty
WDR5-0103
🥰Excellent
Catalog No. T3201Cas No. 890190-22-4
Alias WD-Repeat Protein 5-0103
WDR5-0103 (WD-Repeat Protein 5-0103) is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd: 450 nM).
WDR5-0103
🥰Excellent
Purity: 99.61%
Catalog No. T3201Alias WD-Repeat Protein 5-0103Cas No. 890190-22-4
WDR5-0103 (WD-Repeat Protein 5-0103) is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd: 450 nM).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $38 | In Stock | |
| 10 mg | $64 | In Stock | |
| 25 mg | $131 | In Stock | |
| 50 mg | $232 | In Stock | |
| 100 mg | $343 | In Stock | |
| 200 mg | $489 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $39 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "WDR5-0103"
MAK-683 hydrochloride
T96812170606-94-5In house
MAK683 hydrochloride embryonic ectodermal development (EED) inhibitor, also a potent PRC2 inhibitor, blocked cancer cell proliferation (IC50=1.014nM), with IC50 values of 59, 26, and 89 nM measured in EED Alphascreen, ELISA, and LC-MS assays, respectively.
- $195
Size
QTY
Ruxolitinib phosphate
Cited
Ruxolitinib (INCB-18424) phosphate, INCB018424 phosphate, INCB018424, INC424, INC 424 phosphate
T30431092939-17-7
Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1/2 inhibitor with IC50 of 3.3 nM/2.8 nM. Its selectivity for JAK1/2 is more than 130 times that of JAK3.
- $44
Size
QTY
CitedEPZ015666
GSK3235025
T60761616391-65-1
EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 enzymatic activity.
- $42
Size
QTY
Tofacitinib Citrate
Tofacitinib (CP-690550) Citrate, Tasocitinib citrate, CP-690550 citrate
T2398540737-29-9
Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).
- $32
Size
QTY
MRTX-1719
T402542630904-45-7
MRTX-1719 is a potent and selective inhibitor of the PRMT5/MTA complex with an IC50 value of <10 nM against PRMT5/MTAMTAPDELSDMA cell lines.
- $398
Size
QTY
Tazemetostat Cited
EPZ6438, E-7438
T17881403254-99-8
Tazemetostat (EPZ6438) is a histone methyltransferase EZH2 inhibitor (IC50=11 nM) that is orally active, selective, and SAM-competitive. Tazemetostat exhibits antitumor activity and may be used for the treatment of epithelioid sarcoma/follicular lymphoma.
- $59
Size
QTY
CitedDelgocitinib
JTE-052, Corectim（Delgocitinib）
T150961263774-59-9
Delgocitinib (JTE-052) is a specific JAK (Janus kinase) inhibitor with IC50 values of 2.8, 2.6, 13, and 58 nM for JAK1, JAK2, JAK3, and Tyk2 respectively. Delgocitinib is involved in various inflammatory and autoimmune diseases through JAK-dependent cytokines and can effectively suppress multiple cytokine signaling while inhibiting itching caused by cytokines. It is widely used to treat various inflammatory diseases, including autoimmune diseases and hypersensitivity reactions.
- $172
Size
QTY
Piribedil
Trivastan, Trivastal, EU-4200, ET-495
T32783605-01-4
Piribedil (Trivastan) is a dopamine D2 agonist, used in the treatment of Parkinson's disease.
- $52
Size
QTY
JAK-IN-10
T13571916741-98-5In house
JAK-IN-10 is a JAK inhibitor that can be used for the research of dry eye disorders.
- $79
Size
QTY
Fedratinib Cited
TG-101348, SAR 302503
T1995936091-26-8
Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.
- $45
Size
QTY
CitedDeucravacitinib
BMS-986165
T146871609392-27-9
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12/23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.
- $64
Size
QTY
Baricitinib Cited
LY3009104, INCB028050
T24851187594-09-7
Baricitinib (INCB028050) is a JAK1 and JAK2 inhibitor (IC50=5.9/5.7 nM) with selective and oral activity. Baricitinib has potential anti-inflammatory, immunomodulatory and anti-tumor activity.
- $43
Size
QTY
CitedSelect Batch
Purity:99.61%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | WDR5-0103 (WD-Repeat Protein 5-0103) is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd: 450 nM). |
| Targets&IC50 | WDR5:450 nM |
| Alias | WD-Repeat Protein 5-0103 |
| Molecular Weight | 383.44 |
| Formula | C21H25N3O4 |
| Cas No. | 890190-22-4 |
| Smiles | COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1 |
| Relative Density. | 1.223 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (156.48 mM)  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy WDR5-0103 | purchase WDR5-0103 | WDR5-0103 cost | order WDR5-0103 | WDR5-0103 chemical structure | WDR5-0103 formula | WDR5-0103 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.